New trial
Phase 1 Study of IBI3020 in Advanced Solid Tumors
- Trial ID
- NCT06963281 on ClinicalTrials.gov
- Cancer type
- Solid Tumors
- Location
- 8 Locations
- Published in
- New in Oncology - May 21, 2025
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. is evaluating IBI3020—a CEACAM5-directed monoclonal antibody—in a multicenter, open-label Phase 1 trial for patients with unresectable, locally advanced or metastatic solid tumors, aiming to establish its safety, tolerability, and identify the maximum tolerated or recommended dose for expansion.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings